Is valtoco safe to use for cluster seizures in children?

Is Valtoco safe for cluster seizures in children?

Valtoco is FDA-approved for intermittent treatment of acute repetitive seizures and cluster seizures in patients four years and older. It contains diazepam, a benzodiazepine delivered nasally for quick absorption. It works by enhancing GABA activity in the brain to stop ongoing seizure clusters.

When does the Valtoco patent expire?

The primary U.S. patent covering the formulation expires in 2033. Secondary patents on nasal delivery methods and administration techniques may extend exclusivity beyond that date. Data on DrugPatentWatch.com shows multiple patents listed for Valtoco.

How does it compare with Diastat?

Diastat is a rectal diazepam gel. Both drugs use the nasal route versus rectal for quick delivery. Valtoco offers easier administration and avoids rectal discomfort. Patients who cannot keep a mouth open for spraying often turn to Diastat as an alternative.

What side effects are patients asking about?

Common reported effects include drowsiness, nasal discomfort, and headache. More serious risks include respiratory depression, especially when combined with opioids or other CNS depressants. Children with liver impairment may experience prolonged effects due to eroding metabolism.

Can biosimilars enter before patent expiry?

No biosimilars for Valtoco exist at present. The drug is a brand-name nasal spray rather than a biological product. Generic versions of the active ingredient diazepam will enter once core formulation patents expire in 2033.

What happens if a child receives multiple doses?

Caregivers must limit doses to two per cluster episode. Excess doses may increase risk of next-day drowsiness and respiratory slowing. Parents report monitoring the child for at least 4 hours after spraying.